IGF2BP3 and breast carcinoma: Conversely, within the context of breast cancer, the m6A modification catalyzed by METTL3 not only bolsters the longevity of PD-L1 mRNA transcripts but also facilitates their transcriptional activation, a process that hinges on the recognition of the m6A mark by the IGF2BP3 protein (124).